Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors

Abdullah Aboukarr and Mirella Giudice

ABSTRACT

Background: Monoamine oxidase B (MAO-B) inhibitors are used to treat the motor symptoms of Parkinson disease. Depression is commonly associated with Parkinson disease, and selective serotonin reuptake inhibitors (SSRIs) are often used for its management. Tertiary sources warn that the combination of MAO-B inhibitors and SSRIs can result in increased serotonergic effects, leading to serotonin syndrome.

Objective: To explore the mechanism, clinical significance, and management of this potential drug interaction through a review of the supporting evidence.

Data Sources: PubMed, MEDLINE (1946 forward), Embase (1947 forward), PsycINFO (1806 forward), and International Pharmaceutical Abstracts (1970 forward) were searched on February 4, 2017.

Study Selection and Data Extraction: Studies and case reports describing aspects of the potential interaction between MAO-B inhibitors and SSRIs in patients with Parkinson disease and published in English were identified by both title and abstract.

Data Synthesis: The search identified 8 studies evaluating the potential interaction between SSRIs and the MAO-B inhibitors selegiline and rasagiline. The largest, a retrospective cohort study of 1504 patients with Parkinson disease, found no cases of serotonin syndrome with coadministration of rasagiline and an SSRI. A survey of 63 investigators in the Parkinson Study Group identified 11 potential cases of serotonin syndrome among 4568 patients treated with the combination of selegiline and antidepressants (including SSRIs). In addition, 17 case reports describing the onset of serotonin syndrome with coadministration of an SSRI and either selegiline or rasagiline were identified. Following discontinuation or dose reduction of one or both of the agents, the symptoms of serotonin syndrome gradually resolved in most cases, with none being fatal.

Conclusions: According to the literature, serotonin syndrome occurs rarely, and the combination of SSRI and MAO-B inhibitor is well tolerated. Therefore, SSRIs and MAO-B inhibitors can be coadministered, provided that their recommended doses are not exceeded and the SSRI dose is kept at the lower end of the therapeutic range. Among the SSRIs, citalopram and sertraline may be preferred.

Keywords: Parkinson disease, serotonin syndrome, selegiline, rasagiline, selective serotonin reuptake inhibitor, drug interactions

RÉSUMÉ

Contexte: Les inhibiteurs de la monoamine oxydase B (MAO-B) sont employés dans le traitement des symptômes moteurs de la maladie de Parkinson, maladie à laquelle la dépression est souvent associée et fréquemment traitée à l’aide d’inhibiteurs sélectifs de la recapture de la sérotonine (ISRS). Des sources tertiaires mettent en garde contre la combinaison d’inhibiteurs de la MAO-B et d’ISRS car elle peut mener à une augmentation des effets sérotoninergiques, dégénérant en un syndrome sérotoninergique.

Objectif: Chercher à connaître le mécanisme, la signification clinique et la prise en charge de cette potentielle interaction médicamenteuse en procédant à une revue des preuves à l’appui.


 Sélection des études et extraction des données : Des études et des observations cliniques, publiées en anglais, portant sur des aspects de la potentielle interaction entre les inhibiteurs de la MAO-B et les ISRS chez les patients atteints de la maladie de Parkinson ont été repérées par une recherche ciblant les titres et les résumés.

 Synthèse des données : La recherche a permis de trouver 8 études analysant la potentielle interaction entre les ISRS et deux inhibiteurs de la MAO-B : la sélegiline et la rasagiline. La plus importante d’entre elles, une étude de cohorte rétrospective sur 1504 patients atteints de la maladie de Parkinson, n’a relevé aucun cas de syndrome sérotoninergique en présence d’une prise concomitante de rasagiline et d’un ISRS. Une enquête auprès de 63 chercheurs dans le Parkinson Study Group a permis de relever 11 potentiels cas de syndrome sérotoninergique chez 4568 patients traités avec une combinaison de sélegiline et d’antidépresseurs (notamment des ISRS). De plus, 17 observations cliniques qui décraivaient un début de syndrome sérotoninergique en présence d’une prise concomitante d’un ISRS et de sélegiline ou de rasagiline ont été recensées. Suivant la réduction de la posologie ou l’interruption d’un ou des deux médicaments, les symptômes du syndrome sérotoninergique se sont graduellement résolus dans la plupart des cas, et il n’y a eu aucune mortalité.

Conclusions: Selon la documentation, le syndrome sérotoninergique est rare et la combinaison d’ISRS et d’inhibiteurs de la MAO-B est bien
INTRODUCTION

The monoamine oxidase B (MAO-B) inhibitors selegiline and rasagiline are among the agents used to treat the motor symptoms of Parkinson disease. Depression is commonly associated with Parkinson disease, with up to 50% of patients being affected. The treatment of depression in patients with Parkinson disease should be individualized, with particular emphasis on concomitant therapy. Although selective serotonin reuptake inhibitors (SSRIs) are often used to manage the symptoms of depression associated with Parkinson disease, these drugs have the potential to worsen the motor symptoms of the disease (tremor, restless legs, and periodic limb movement). Furthermore, a potential interaction between SSRIs and MAO-B inhibitors can lead to serotonin syndrome. This review explores the mechanism of, supporting evidence for, clinical significance of, and management of potential serotonin syndrome with concomitant use of MAO-B inhibitors and SSRIs.

DIAGNOSTIC CRITERIA FOR SEROTONIN SYNDROME

Serotonin syndrome is a measure of central nervous system (CNS) hyperexcitability in relation to an excess of serotonin. This hyperexcitability can manifest in multiple ways, and ultimately there is no true “gold standard” for the diagnosis of serotonin syndrome. Published diagnostic criteria have attempted to identify symptoms or symptom combinations that best capture the nature of CNS hyperexcitability related to an excess of serotonin. Serotonin syndrome can manifest as symptoms that range from mild to life-threatening. Initially, the patient may present with akathisia and tremor, followed by mental status changes and inducible clonus. The clonus can become sustained, and may then evolve to muscular rigidity or hypertonicity. Hyperthermia is a symptom that manifests later; it can be life-threatening. Most cases of serotonin syndrome present within 24 h of a dose increase or initiation of a new serotonergic agent.

Sternbach first suggested diagnostic criteria for serotonin syndrome in 1991. The Sternbach criteria require at least 3 of the following clinical features, coincident with adding or increasing the dose of a serotonergic agent: mental status changes, agitation, myoclonus, hyperreflexia, diaphoresis, shivering, tremor, diarrhea, incoordination, and fever. Despite their widespread use, the Sternbach criteria have some limitations. They can be nonspecific, because of heavy reliance on mental status changes. Furthermore, the inclusion of incoordination (ataxia), a cerebellar feature, is controversial, because serotonin toxicity is not known to affect the cerebellum. Any patient who is agitated or confused may also appear ataxic or uncoordinated. Lastly, the Sternbach criteria were developed on the basis of a series of published cases; therefore, any clinical features not identified as features of serotonin syndrome by the authors of the original cases may have been missed.

In 2003, Dunkley and others undertook to improve the Sternbach criteria, and developed the Hunter serotonin toxicity criteria (HSTC). According to these criteria, a diagnosis of serotonin syndrome requires the presence of a serotonergic agent and one of the following conditions:

- clonus
- inducible clonus AND agitation or diaphoresis
- ocular clonus AND agitation or diaphoresis
- tremor AND hyperreflexia
- hypertonicity AND temperature > 38°C AND ocular clonus or inducible clonus

The HSTC are currently the most accurate criteria for diagnosing serotonin syndrome, being both more sensitive and more specific than the Sternbach criteria. Nonetheless, the HSTC have their shortcomings. They are based solely on cases of SSRI overdose, making them potentially nongeneralizable to cases of serotonin syndrome involving therapeutic doses. In addition, a subset of cases used to derive the criteria were also used for validation, leading to a potential overestimate of validity. Lastly, clonus or hyperreflexia may not be elicited in patients with severe serotonin syndrome who have peripheral neuropathy or muscle rigidity, which can cloud the clinical diagnosis of serotonin syndrome.

MECHANISM OF DRUG INTERACTION

MAO exists as 2 isoforms, MAO-A and MAO-B. Inhibition of MAO-A reduces the metabolism of both serotonin and noradrenaline, whereas inhibition of MAO-B does not affect the metabolism of these neurotransmitters, unless sufficient doses (as described below) are used. Inhibition of MAO-B, the major
isofrom in the human brain, prevents the breakdown of extracellular levels of dopamine in the striatum. The resulting increase in dopaminergic activity in the striatum may explain the mechanism by which MAO-B inhibitors exert their beneficial effects in Parkinson disease.\textsuperscript{16,17} Inhibition of MAO can also be reversible or irreversible; irreversible inhibitors can lead to longer-lasting toxic reactions caused by MAO inhibition, including serotonin syndrome.\textsuperscript{18} Selegiline and rasagiline, both irreversible MAO-B inhibitors, are selective for MAO-B at therapeutic doses of 10 mg daily and 1 mg daily, respectively, for patients with Parkinson disease. At higher doses, they lose selectivity and inhibit both MAO-B and MAO-A. Higher doses of MAO-B inhibitors alone have resulted in serotonin syndrome.\textsuperscript{17,18}

Serotonin syndrome results from increased serotonergic activity in the CNS. The SSRIs increase serotonin activity by blocking the reuptake of serotonin from synapses.\textsuperscript{3} Serotonin receptors are classified into 7 families, which are designated 5-HT\textsubscript{1} to 5-HT\textsubscript{7}, with specific families having multiple subtypes. The development of serotonin syndrome has not been attributed to one specific receptor; however, evidence suggests that agonism of the 5-HT\textsubscript{2A} subtype may play a considerable role. The 5-HT\textsubscript{1A} subtype may also be implicated in the development of serotonin syndrome through a pharmacodynamic interaction in which increased synaptic concentrations of serotonin can saturate all receptor subtypes.\textsuperscript{10}

MAO-A inhibitors can augment the serotonergic effects of SSRIs by preventing the breakdown of serotonin.\textsuperscript{6,19} Consequently, serotonin syndrome has been reported with concomitant use of SSRIs and nonselective MAO inhibitors (e.g., phenelzine, tranylcypromine), as well as with selective

Table 1. Recommendations for Management of the Interaction between MAO-B Inhibitors and SSRIs from Tertiary Sources

<table>
<thead>
<tr>
<th>Reference</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selegiline product monograph\textsuperscript{16}</td>
<td>Concomitant use of selegiline and fluoxetine should be avoided. Administration should be separated by a washout period of at least 5 weeks after discontinuing fluoxetine and starting an MAO inhibitor, and at least 2 weeks after discontinuing an MAO inhibitor and starting fluoxetine.</td>
</tr>
<tr>
<td>Rasagiline product monograph\textsuperscript{17}</td>
<td>Concomitant use of rasagiline and SSRIs should be avoided. Administration should be separated by a washout period of at least 2 weeks after discontinuing rasagiline and starting an SSRI, and at least 2 weeks after discontinuing most SSRIs (5 weeks after discontinuing fluoxetine) and starting rasagiline.</td>
</tr>
<tr>
<td>Selegiline product label\textsuperscript{27}</td>
<td>Concomitant use of selegiline and SSRIs should be avoided. Administration should be separated by a washout period of at least 2 weeks after discontinuing selegiline and starting an SSRI, and at least 5 weeks after discontinuing fluoxetine and starting selegiline.</td>
</tr>
<tr>
<td>Rasagiline product label\textsuperscript{28}</td>
<td>Concomitant use of rasagiline and SSRIs is not recommended. Administration should be separated by a washout period of at least 2 weeks after discontinuing rasagiline and starting an SSRI, and at least 5 weeks after discontinuing fluoxetine and starting rasagiline.</td>
</tr>
<tr>
<td>Lexi-Interactions database: SSRIs and MAO inhibitors\textsuperscript{5}</td>
<td>Concomitant use is contraindicated. Administration should be separated by a washout period of at least 1–2 weeks, and 5 weeks for fluoxetine, depending on the half-life of the agent being discontinued.</td>
</tr>
<tr>
<td>Interaction Checking (MicroMedex database): SSRIs and MAO inhibitors\textsuperscript{7}</td>
<td>Concomitant use is contraindicated. Selegiline: Administration should be separated by a washout period of at least 2 weeks after discontinuing selegiline and starting an SSRI, and at least 2 weeks after discontinuing most SSRIs (5 weeks after discontinuing fluoxetine, and 1 week after discontinuing sertraline) and starting selegiline. Rasagiline: Administration should be separated by a washout period of at least 2 weeks after discontinuing rasagiline and starting an SSRI, and at least 2 weeks after discontinuing most SSRIs (5 weeks after discontinuing fluoxetine) and starting rasagiline.</td>
</tr>
<tr>
<td>Medscape Drug Interaction Checker: SSRIs and MAO inhibitors\textsuperscript{6}</td>
<td>Selegiline: Concomitant use of selegiline and SSRIs is contraindicated. Rasagiline: Concomitant use of rasagiline and SSRIs should be avoided. Administration should be separated by a washout period of at least 14 days (≥ 5 weeks after discontinuing fluoxetine).</td>
</tr>
<tr>
<td>Stockley’s Drug Interactions\textsuperscript{32}</td>
<td>This reference refers to the manufacturers’ recommendations regarding management of the drug interaction.</td>
</tr>
<tr>
<td>UpToDate: Management of nonmotor symptoms in Parkinson disease\textsuperscript{4}</td>
<td>MAO-B inhibitors should be prescribed only at recommended doses. Caution is advised when combining MAO-B inhibitors and SSRIs because of the risk of serotonin syndrome.</td>
</tr>
<tr>
<td>Physician Guide: Non-motor Symptoms of Parkinson’s Disease\textsuperscript{2}</td>
<td>The interaction between MAO-B inhibitors and SSRIs is theoretical and may not be clinically relevant. Selegiline has been combined with SSRIs for many years with only infrequent reports of serotonin syndrome; data on rasagiline are limited. However, patients must be warned of this theoretical interaction as it commonly flagged by pharmacy management software.</td>
</tr>
</tbody>
</table>

MAO-B = monoamine oxidase B; SSRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor.
MAO-A inhibitors (e.g., moclobemide).\textsuperscript{6,20} According to references reporting these interactions, patients have experienced symptoms such as agitation, confusion, myoclonus, rigidity, nausea, and insomnia; some cases were fatal.\textsuperscript{6,20} MAO-B inhibitors have also been implicated in the development of serotonin syndrome, as discussed below (see “Summary of Evidence”).

RECOMMENDATIONS FROM TERTIARY REFERENCES

The product monographs for escitalopram, paroxetine, fluoxetine, sertraline, citalopram, and fluvoxamine all recommend avoiding their concurrent use with selective and nonselective MAO inhibitors and separating administration of these drugs by a washout period ranging from 2 to 5 weeks.\textsuperscript{21-26} The product monograph for sertraline reports serious, sometimes fatal reactions associated with concomitant use of selegiline.\textsuperscript{24} Various drug interaction references and the product monographs and labels for selegiline and rasagiline (Table 1) reiterate these recommendations.\textsuperscript{2,4,6-8,16,17,20,27,28}

**SUMMARY OF EVIDENCE**

A search of PubMed, MEDLINE (1946 forward), Embase (1947 forward), PsyCINFO (1806 forward), and International Pharmaceutical Abstracts (1970 forward) was conducted on

### Table 2 (part 1 of 2). Studies Examining the Interaction between Selegiline or Rasagiline and SSRIs

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Population</th>
<th>Interventions and Duration of Therapy</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hilli et al. (2009)\textsuperscript{42}</td>
<td>Open, sequential-setting study</td>
<td>12 healthy male volunteers</td>
<td>Rasagiline 1 mg/day + escitalopram 10 mg/day OR Rasagiline 1 mg/day Duration: 7 days</td>
<td>Combination was generally well tolerated, with 91% of adverse events classified as mild or moderate. One patient had severe headache and another had severe tiredness.</td>
</tr>
<tr>
<td>Laine et al. (1997)\textsuperscript{32}</td>
<td>Part 1: Randomized, double-blind, parallel study, Part 2: Open-label, crossover study</td>
<td>18 healthy male volunteers; mean age 24 years (citalopram) and 25 years (placebo)</td>
<td>Part 1 Group A: citalopram 20 mg/day for 14 days, with selegiline 10 mg/day added for days 11–14 Group B: Placebo for 14 days, with selegiline 10 mg/day added for days 11–14 Part 2 After a 5-week washout period, patients from group A were crossed over to selegiline 10 mg/day for 4 days</td>
<td>Combination therapy was well tolerated. The most frequent adverse events were headache, dry mouth, sweating, nausea, and sleep disturbances. Reported adverse events were similar in both groups, both before and after initiating selegiline. No cases of serotonin syndrome. Lack of clinically relevant interaction.</td>
</tr>
<tr>
<td>Panisset et al. (2014)\textsuperscript{31}</td>
<td>Multicentre, retrospective cohort study</td>
<td>1504 patients with PD; mean age 67.0 years; 58.8% male</td>
<td>Group 1: rasagiline + antidepressant (74.5% SSRI<em>s; 10.0% were using &gt; 1 antidepressant) Duration: 50.5–53.5 weeks Group 2: antidepressant only (77.0% SSRI</em>s; 16.6% were using &gt; 1 antidepressant) Duration: 51.7–80.9 weeks Group 3: rasagiline</td>
<td>No cases of serotonin syndrome in any group.</td>
</tr>
</tbody>
</table>

Based on the Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder,\textsuperscript{39} SSRIs vary in their overall potential for drug–drug interactions: citalopram and escitalopram have minimal or low potential; sertraline has moderate potential; and fluoxetine, fluvoxamine, and paroxetine have high potential. Selegiline is also classified as having a higher potential for drug–drug interactions relative to other antidepressants; rasagiline is not classified.\textsuperscript{39} Selegiline is metabolized primarily via the cytochrome P450 isozymes CYP2B6, CYP2C9, CYP3A4, and CYP2A6, whereas rasagiline is metabolized by CYP1A2.\textsuperscript{40,41}
Table 2 (part 2 of 2). Studies Examining the Interaction between Selegiline or Rasagiline and SSRIs

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Population</th>
<th>Interventions and Duration of Therapy</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard et al. (1997)</td>
<td>Survey of investigators from Parkinson Study Group</td>
<td>4568 patients with PD</td>
<td>Selegiline + antidepressant (including SSRIs); doses not stated</td>
<td>• 11 patients (0.24%) experienced symptoms possibly related to serotonin syndrome; 2 patients (0.04%) experienced symptoms judged to be serious. • See Table 3 for details about SSRI cases for which detailed information was available.</td>
</tr>
<tr>
<td>Ritter and Alexander (1997)</td>
<td>Retrospective chart review</td>
<td>28 male patients with PD; mean age 68 years</td>
<td>Selegiline + antidepressant (7/40 SSRI)</td>
<td>• One possible case of serotonin syndrome involving selegiline 10 mg/day and fluoxetine 20 mg/day.</td>
</tr>
<tr>
<td>Rhimer et al. (2000)</td>
<td>Observational study</td>
<td>8 patients with PD; mean age 74.1 years, 75% male</td>
<td>Selegiline 5–10 mg/day + citalopram 20 mg/day</td>
<td>• No cases of serotonin syndrome. • No other adverse events. Duration: 8 weeks</td>
</tr>
<tr>
<td>Waters (1994)</td>
<td>Retrospective chart review</td>
<td>23 patients with PD; mean age 64.6 years, 56.5% male</td>
<td>Selegiline 5–10 mg/day + fluoxetine 5–40 mg/day</td>
<td>• No cases of serotonin syndrome. • One patient experienced worsened parkinsonian tremor, both with fluoxetine alone and with the combination of fluoxetine and selegiline.†</td>
</tr>
<tr>
<td>Toyama and Iacono (1994)</td>
<td>Case series</td>
<td>16 patients with PD</td>
<td>Selegiline 5–10 mg/day + SSRI (sertraline 25–100 mg/day or paroxetine 10–40 mg/day) with or without trazodone 25–150 mg/day</td>
<td>• No cases of serotonin syndrome. • No other adverse events. Duration: 2–30 weeks (mean 10 weeks)</td>
</tr>
</tbody>
</table>

PD = Parkinson disease, SSRI = selective serotonin reuptake inhibitor.

*Mean SSRI doses in antidepressant + rasagiline group and antidepressant-only group, respectively: citalopram 23.7 and 26.0 mg, escitalopram 13.8 and 14.2 mg, fluoxetine 24.1 and 27.2 mg, paroxetine 22.3 and 22.9 mg, and sertraline 78.0 and 85.0 mg.

†There were a total of 40 selegiline–antidepressant combinations, because some patients were treated with more than 1 trial of different antidepressants.

†Tremor improved after discontinuation of fluoxetine.

February 4, 2017, using the MeSH (Medical Subject Heading) term “drug interaction” and combined keywords “selegiline and SSRI,” “rasagiline and SSRI,” “fluoxetine and selegiline,” “fluvoxamine and selegiline,” “sertraline and selegiline,” “paroxetine and selegiline,” “citalopram and selegiline,” “escitalopram and selegiline,” “fluoxetine and rasagiline,” “fluvoxamine and rasagiline,” “sertraline and rasagiline,” “paroxetine and rasagiline,” “citalopram and rasagiline” and “escitalopram and rasagiline.” Studies and case reports were identified by both title and abstract. Duplicate citations, identified by author, journal, and date of publication, were excluded. Only studies and case reports published in English were considered.

Studies

Eight relevant studies were identified (3 retrospective studies, 1 observational study, 1 open sequential-setting study, 1 case series, 1 survey study, and 1 randomized controlled trial) that evaluated the potential for an interaction between SSRIs and the MAO-B inhibitors selegiline and rasagiline (Table 2).31-33,37,38,42-44 Most of the studies had a small sample size, and most evaluated selegiline; this finding was unsurprising, given that selegiline was approved by the US Food and Drug Administration (FDA) in 1989 and has therefore been available much longer than rasagiline, which was approved by the FDA in 2006.45

Two studies involved healthy patients, so their results may not be applicable to patients with Parkinson disease.32,42 In one of these studies,42 which involved rasagiline and escitalopram, the area under the curve (AUC) for rasagiline increased by 42% (p < 0.0001) and oral clearance decreased by 35% (p < 0.001) after 7 days of combination therapy, relative to rasagiline treatment alone. The elimination half-life, peak plasma concentration (Cmax), and time from drug intake to peak concentration (tmax) of rasagiline were not significantly affected by escitalopram.42 In the other study,32 which involved selegiline and citalopram, the AUC of selegiline decreased by 29% with concomitant citalopram, relative to selegiline alone; Cmax and tmax were not significantly affected. Citalopram pharmacokinetics were unaffected, and the authors reported a lack of clinically relevant pharmacokinetic interaction.32

The largest study, involving rasagiline,31 was a multicentre, retrospective cohort study, in which the authors systematically evaluated the incidence of serotonin syndrome among patients...
taking rasagiline plus an antidepressant. Study centres were
selected from individual neurology practices with medical records
for 50 or more patients with Parkinson disease who had received
rasagiline, 50 or more patients with Parkinson disease who had
received an antidepressant, and 50 or more patients with
Parkinson disease who had received the combination of rasagiline
and an antidepressant. Serotonin syndrome was defined using the
HSTC, which to date are the most sensitive and specific criteria
for diagnosing serotonin syndrome.\(^3\) Out of 1507 patients
initially considered, all with Parkinson disease, 471 were taking
rasagiline in combination with an antidepressant (351 or 74.5%
using SSRIs), 511 were taking rasagiline without an antidepressant
(3 of whom did not meet the eligibility criteria and were later ex-
cluded from analysis), and 525 were taking antidepressants (404
or 77.0% using SSRIs) without rasagiline. The mean SSRI doses
in the antidepressant + rasagiline group and the antidepressant-
only group were, respectively, citalopram 23.7 and 26.0 mg,
escitalopram 13.8 and 14.2 mg, fluoxetine 24.1 and 27.2 mg,
paroxetine 22.3 and 22.9 mg, and sertraline 78.0 and 85.0 mg,
which fall mainly at the lower end of the therapeutic ranges of
these drugs. Of the 1419 patients (94.3%) with known outcomes,
none experienced serotonin syndrome. The authors stated that
the lack of serotonin syndrome cases suggests a rarer-than-
expected incidence of the syndrome, which was below the study’s
detection threshold.\(^3\) They further stated that future studies
should increase the sample size to assess the true incidence of
serotonin syndrome with concomitant use of rasagiline and
antidepressants.\(^3\) This study had both strengths and limitations.
One major strength was the independent, systematic review of
each case according to the HSTC, which ensured that cases of
serotonin syndrome that might not have been properly recognized
during a medical encounter were reassessed against robust criteria
for this syndrome. Conversely, a major limitation was the
retrospective study design, which meant that roughly 20% of
medical records were unavailable for ascertainment of serotonin
syndrome. Furthermore, there was limited access to the medical
records of deceased patients, because of the requirement for
informed consent at several study centres, which potentially
prevented the capture of further cases of serotonin syndrome.
A final limitation was the potential dismissal of symptoms of
serotonin syndrome as features of the underlying disease. As such,
practitioners might not have documented unusual findings as
symptoms of serotonin syndrome, giving rise to false negatives.\(^3\)

A survey of 63 investigators in the Parkinson Study Group
utilized a standardized questionnaire to identify patients treated
with the combination of selegiline and antidepressants.\(^3\) Forty-
seven investigators responded, which allowed identification of a
total of 4568 patients who were taking this combination. Of these
patients, 11 (0.24%) experienced symptoms “possibly consistent”
with serotonin syndrome, with 2 patients having symptoms that
were considered serious. Details were provided for only 5 patients,
and one of these cases was already published (in 2 reports).\(^29,30\) All
5 patients had used an SSRI (see “PSG cases” in Table 3 for further
details).\(^29,30,43\) Because details were unavailable for the remaining
6 patients, it is unknown whether they were taking an SSRI
or another antidepressant.\(^43\) In addition to their survey of the
Parkinson Study Group investigators, the authors obtained a
summary of all possible cases of drug interactions with concomi-
tant use of selegiline and an antidepressant that had been subm-
ituted to the FDA between 1989 and 1996. Fifty-seven cases were
identified, of which 27 involved an SSRI. From these 27 cases,
only 2 were stated as having possibly fulfilled the Sternbach criteria
for serotonin syndrome (see “FDA cases” in Table 3 for further
details).\(^43\) Lastly, the authors conducted a MEDLINE search and
reviewed bibliographies for published cases of adverse events as-
associated with concomitant use of selegiline and an antidepressant.
Six cases were identified, 5 of which (including one of the cases
identified by the Parkinson Study Group survey) involved an SSRI
(see “published cases” in Table 3 for further details).\(^43\)

Apart from these 11 potential cases of serotonin syndrome
(4 cases from the survey [excluding the published case], 2 cases
submitted to the FDA, and 5 cases from the MEDLINE search
[including the case identified in the survey]), a retrospective chart
review of 28 patients with Parkinson disease identified 1 possible
case of serotonin syndrome.\(^3\) The patient in question experienced
increased nervousness, anxiety, tremor, and confusion less than
1 week after starting fluoxetine 20 mg/day (in addition to
selegiline 10 mg/day). Although the authors stated that the
reaction was consistent with serotonin syndrome, it was not
possible to establish a firm diagnosis. Soon after stopping
fluoxetine, the patient’s symptoms improved, but they had not
completely resolved 3 weeks later.\(^3\)

Overall, the combination of SSRI and MAO-B inhibitor was
well tolerated in these studies, with 12 possible cases of serotonin
syndrome (1 additional case from the retrospective chart review).
One additional patient experienced worsening of a parkinsonian
tremor, which was attributed to fluoxetine.\(^3\) The evaluated doses
of selegiline and rasagiline were both within the recommended
range for Parkinson disease, and the doses of SSRIs were generally
at the lower end of the therapeutic range for depression. From
these studies, it appears that selegiline or rasagiline can be used
with an SSRI, provided that the recommended doses of both
agents are not exceeded and, ideally, the SSRI dose is kept at the
lower end of the therapeutic range. However, further studies using
larger sample sizes would be welcome to determine the true
incidence of this drug interaction.

**Case Reports**

Although the largest study found no evidence of a clinically
relevant interaction between MAO-B inhibitors and SSRIs,\(^4\) and
only 12 possible cases of serotonin syndrome were identified in
other studies, 6 further case reports have described the onset of
<table>
<thead>
<tr>
<th>Study and Patient</th>
<th>MAO-B Inhibitor*</th>
<th>SSRI*</th>
<th>Onset of Symptoms</th>
<th>Clinical Presentation</th>
<th>Outcome</th>
<th>Hunter Criteria 13</th>
<th>Sternbach Criteria 12 †</th>
</tr>
</thead>
<tbody>
<tr>
<td>70-year-old man</td>
<td>Selegiline</td>
<td>Sertraline</td>
<td>2 weeks after adding SSRI</td>
<td>Worsened PD symptoms, agitation, orthostatic hypotension, confusion</td>
<td>Could not be assessed on basis of worsened PD symptoms</td>
<td>No; agitation alone does not fulfill criteria.</td>
<td></td>
</tr>
<tr>
<td>67-year-old man</td>
<td>Selegiline</td>
<td>Fluoxetine</td>
<td>4 months after adding SSRI</td>
<td>Worsened PD symptoms, agitation</td>
<td>Could not be assessed on basis of worsened PD symptoms</td>
<td>No; agitation alone does not fulfill criteria.</td>
<td></td>
</tr>
<tr>
<td>73-year-old woman</td>
<td>Selegiline</td>
<td>Fluoxetine</td>
<td>A few weeks after adding SSRI</td>
<td>Urinary incontinence, orthostatic hypotension, syncope, agitation</td>
<td>Could not be assessed on basis of worsened PD symptoms</td>
<td>No; agitation alone does not fulfill criteria.</td>
<td></td>
</tr>
<tr>
<td>57-year-old woman</td>
<td>Selegiline, dose increased</td>
<td>Fluoxetine</td>
<td>A few weeks after adding SSRI</td>
<td>Worsening headaches, diaphoresis, increased blood pressure (190/100 mm Hg)</td>
<td>Fluoxetine dose reduced, symptoms resolved</td>
<td>No; diaphoresis alone does not fulfill criteria.</td>
<td></td>
</tr>
<tr>
<td>46-year-old woman</td>
<td>Selegiline, dose increased</td>
<td>Fluoxetine</td>
<td>The next month after adding SSRI</td>
<td>Shivering, vasoconstriction (cold hands, blue and mottled fingers), elevated blood pressure (190/100 mm Hg)</td>
<td>Selegline and fluoxetine discontinued within a few days</td>
<td>Ataxia improved over 6 weeks, Fluoxetine reduced to 10 mg/day after 1 month.</td>
<td></td>
</tr>
</tbody>
</table>

*Note: MAO-B Inhibitor refers to Selegiline or Rasagiline, SSRI refers to Sertraline or Fluoxetine.

For permission to reprint multiple copies or to order presentation-ready copies for distribution, contact CJHP at publications@cshp.ca
<table>
<thead>
<tr>
<th>Study and Patient</th>
<th>MAO-B Inhibitor*</th>
<th>SSRI*</th>
<th>Onset of Symptoms</th>
<th>Clinical Presentation</th>
<th>Outcome</th>
<th>Hunter Criteria(^3)</th>
<th>Sternbach Criteria(^4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garcia-Monco et al. (1995)(^6)</td>
<td>Selegiline 10 mg/day</td>
<td>Fluoxetine, dose not stated</td>
<td>Days after adding fluoxetine</td>
<td>Diaphoresis, distal tremor, confusion, moderate increase in blood pressure</td>
<td>Fluoxetine discontinued. Symptoms resolved and did not recur upon initiation of amitriptyline.</td>
<td>No; combination of diaphoresis and tremor does not fulfill criteria.</td>
<td>Yes; combination of diaphoresis, tremor, and confusion (mental status changes) fulfills criteria. Onset of symptoms coincident with adding fluoxetine.</td>
</tr>
<tr>
<td>Montastruc et al. (1993)(^\circ)</td>
<td>Selegiline 10 mg/day</td>
<td>Fluoxetine 20 mg/day</td>
<td>1 month after adding SSRI</td>
<td>“Probable” generalized tonic-clonic seizure, elevated blood pressure (250/130 mm Hg), headache, flushes, palpitations</td>
<td>Selegiline and fluoxetine discontinued. Blood pressure and urine catecholamines normalized within 2 days.</td>
<td>No; tonic-clonic seizure may have resulted from hyperthermia.</td>
<td>No</td>
</tr>
<tr>
<td>Richard et al. (1997)(^4)</td>
<td>Selegiline, dose not stated</td>
<td>Fluoxetine, dose not stated</td>
<td>After 8 days of concomitant therapy</td>
<td>“Serotonergic reaction”</td>
<td>Not stated</td>
<td>Could not be assessed, based on lack of description of symptoms of “serotonergic reaction”.</td>
<td>Could not be assessed, based on lack of description of symptoms of “serotonergic reaction”.</td>
</tr>
<tr>
<td>Suphanklang et al. (2015)(^5)</td>
<td>Rasagiline, dose not stated</td>
<td>Escitalopram, dose not stated</td>
<td>2 days after adding rasagiline</td>
<td>High-grade fever, confusion, agitation, hallucinations, behavioural changes</td>
<td>Rasagiline and escitalopram discontinued.</td>
<td>Could not be assessed because only abstract was available for case information; agitation alone does not fulfill criteria.</td>
<td>Yes; combination of fever, confusion (mental status changes), and agitation fulfills criteria. Onset of symptoms coincident with adding paroxetine.</td>
</tr>
<tr>
<td>Duval et al. (2013)(^6)</td>
<td>Rasagiline 1 mg/day</td>
<td>Sertraline 100 mg/day</td>
<td>1 week after sertraline dose increase from 50 to 100 mg/day</td>
<td>Agitation, delusion, altered consciousness, diaphoresis with hyperthermia (38.5°C), unstable blood pressure, generalized myoclonic tremor with rigidity, hyperreflexia</td>
<td>Rasagiline and sertraline discontinued. Symptoms resolved within 3 days.</td>
<td>Yes; combination of tremor and hyperreflexia fulfills criteria.</td>
<td>Yes; combination of agitation, diaphoresis, myoclonic tremor, and hyperreflexia fulfills criteria.</td>
</tr>
<tr>
<td>Sanyal et al. (2010)(^7)</td>
<td>Selegiline 5 mg/day</td>
<td>Escitalopram 10 mg/day</td>
<td>1 week after adding SSRI</td>
<td>Agitation, restlessness, shivering, sweating, diarrhea, hyperthermia (102°F), tremor, ataxia, hyperreflexia, mydriasis, tachycardia, hypotension, confusion, anxiety. ICU admission was required</td>
<td>Selegiline and escitalopram discontinued, cyproheptadine started. Symptoms improved and vital signs stable next day.</td>
<td>Yes; combination of tremor and hyperreflexia fulfills criteria.</td>
<td>Yes; combination of agitation, shivering, sweating (diaphoresis), diarrhea, tremor, hyperreflexia, and confusion (mental status changes) fulfills criteria. Onset of symptoms coincident with adding escitalopram.</td>
</tr>
</tbody>
</table>

continued on page 204
Table 3 (part 3 of 3). Case Reports of Possible Serotonin Syndrome Induced by Concomitant Use of Selegiline or Rasagiline with SSRI

<table>
<thead>
<tr>
<th>Study and Patient</th>
<th>MAO-B Inhibitor*</th>
<th>SSRI*</th>
<th>Onset of Symptoms</th>
<th>Clinical Presentation</th>
<th>Outcome</th>
<th>Hunter Criteria 13</th>
<th>Sternbach Criteria 12 †</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hébant et al. (2016) 50</td>
<td>Rasagiline, 1 mg/day</td>
<td>Paroxetine, 20 mg/day</td>
<td>3 weeks after adding SSRI</td>
<td>Fever, profuse sweating, confusion, hyperventilation, tremor affecting all 4 limbs, which was different from patient's usual PD tremor</td>
<td>Rasagiline and paroxetine discontinued. Symptoms resolved within a few days.</td>
<td>No; tremor alone does not fulfill criteria.</td>
<td>Yes; fever, sweating, confusion (mental status changes), and tremor fulfill criteria. Onset of symptoms coincident with adding paroxetine.</td>
</tr>
<tr>
<td>72-year-old man</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noyes et al. (1995) 51</td>
<td>Selegiline, dose not stated</td>
<td>Fluoxetine, dose not stated</td>
<td>After 9 weeks of concomitant therapy</td>
<td>Lethargy, malaise, progressive myoclonic jerking, grand mal seizure</td>
<td>Fluoxetine discontinued after grand mal seizure. Seven days later, patient had acute delirium, convulsive movements, akathisia, and unresponsiveness. Selegiline discontinued. Symptoms resolved within 1 week.</td>
<td>No; myoclonus is a symptom of serotonin syndrome, but does not fulfill criteria.</td>
<td>No; myoclonus is a symptom of serotonin syndrome, but does not fulfill criteria.</td>
</tr>
<tr>
<td>72-year-old man</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kurlan and Dimitopulos (1992) 34</td>
<td>Selegiline, dose not stated</td>
<td>Fluoxetine, dose not stated</td>
<td>Within 3 months of concomitant therapy</td>
<td>Manic episode</td>
<td>Selegiline discontinued. Two months later, patient experienced another manic episode while not on selegiline.</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>41-year-old man</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AE = adverse event, FDA = Food and Drug Administration (US), ICU = intensive care unit, MAO-B = monoamine oxidase B, PD = Parkinson disease, PSG = Parkinson Study Group, SSRI = selective serotonin reuptake inhibitor.

*At stated doses until development of symptoms.
†Onset of symptoms deemed coincident if reaction developed within 4 weeks, the upper limit of the clinical reports used to develop the Sternbach criteria.12
possible serotonin syndrome with coadministration of an SSRI and either selegiline or rasagiline.34–36,47-51 Table 3 describes these cases, in addition to the 11 cases identified by the Parkinson Study Group (including the survey, literature search, and review of FDA-reported cases).29,30,34-36,43,46-51 For one published case identified by the Parkinson Study Group, we noted discrepancies between their description13 and the reports of the original authors.29,30 As such, the authors’ original description29,30 has been included in Table 3.

The onset of serotonin syndrome varied from days to weeks following a dose increase (1 case only) or initiation of the new serotonergic agent (most reports). This finding is inconsistent with the statement by Mason and others11 that most cases of serotonin syndrome manifest within 24 h after a dose change or initiation of a serotonergic agent; however, the observations of those authors were based on only 41 patients. Although most of these patients had underlying diseases, none had Parkinson disease.11 In addition, selegiline was not implicated in any of the cases, rasagiline had not yet been approved,45 and a substantial proportion of the patients (26%) experienced serotonin syndrome after more than 24 h, with the longest period of symptom onset being 36 days.11 Therefore, serotonin syndrome cannot be ruled out on the basis of timeframe alone, and a specific timeframe is not a requirement to fulfill the HSTC.15

The most commonly implicated MAO-B inhibitor and SSRI were selegiline and fluoxetine, respectively, likely because of their lengthier market approval and the relatively longer half-life of fluoxetine. This longer half-life is important because changes in plasma concentration will not be fully observed for several weeks. Similarly, when fluoxetine is discontinued, plasma concentrations drop slowly, and the drug remains in the body for several weeks.35 In these case reports, the doses of the MAO-B inhibitor were within the recommended range for Parkinson disease, and the doses of the SSRI were at the lower end of the therapeutic range for depression.16,17,21,24

Following discontinuation or dose reduction of one or both serotonergic agents, symptoms of serotonin syndrome gradually resolved in most cases; no cases were fatal. In 2 cases, the patients also experienced worsened symptoms of Parkinson disease. In the first case, worsening of tremor persisted despite sertraline discontinuation.43 In the second case, worsening of tremor also persisted, but no mention was made of whether the SSRI was discontinued; notably, however, the dose of selegiline had been reduced.43 It is interesting to note the similarities between the motor symptoms of Parkinson disease, specifically resting tremor and rigidity, and the motor symptoms of serotonin syndrome.1,12 Both of these cases were published before development of the HSTC, which include both tremor and hypertonicity as clinical features of serotonin syndrome.13 Therefore, a mild form of serotonin syndrome might have been considered, had the HSTC been available at the time of the event in these 2 cases.

In the case presented by Montastruc and others,45 the patient experienced a tonic–clonic seizure. Seizures are more severe complications of serotonin syndrome, often associated with hyperthermia.10,14 The authors did not report the patient’s temperature. For this reason, it was not possible to confirm the cause of the seizure as serotonin syndrome.

Cyproheptadine has been proposed as an off-label treatment for serotonin syndrome. It is a histamine-1 receptor antagonist with additional nonspecific binding at the 5-HT1A and 5-HT2A receptors. It is recommended as an antidote for serotonin syndrome,10 despite a lack of evidence for its efficacy. The suggested dosage is 12 mg initially, followed by 2 mg every 2 h, or 4–8 mg every 6 h until symptoms are controlled. Because of its anticholinergic activity, it causes sedation.10,14,52 In only one of the identified cases was cyproheptadine reported as having been used to manage serotonin syndrome.49 The dosing in this case differed somewhat from the previously proposed dosing: it was prescribed as 4 mg orally every 2–4 h, with up to 30 mg per day. The patient’s vital signs stabilized, and her symptoms had improved by the next day.49

Four cases of serotonin syndrome47–50 were reported after publication of the HSTC in 2003, and we determined that 2 of them met these criteria.48,49 Fulfillment of the HSTC in these 2 cases is noteworthy because it may indicate that the HSTC are emerging as a new standard for diagnosis. It may also suggest that the HSTC can be applied to cases of serotonin syndrome occurring in patients who receive therapeutic doses, despite the criteria being based solely on cases of SSRI overdose. Of these 2 cases, Duval and others48 used the HSTC for their diagnosis of serotonin syndrome, whereas Sanyal and others49 used the Sternbach criteria. Conversely, we determined that all 4 of the cases published after 2003 met the Sternbach criteria,47–50 which would suggest that these criteria are still being used to diagnose serotonin syndrome. Of the 2 cases that we deemed as not meeting the HSTC criteria, the case reported by Suphanklang and others47 would not be classified as serotonin syndrome, on the basis of information available in the abstract; the full article could not be obtained for examination. In the other case, Hébant and others50 diagnosed serotonin syndrome with the Sternbach criteria and made no mention of the HSTC.

Three further case reports (describing 2 individual patients) did not explicitly mention serotonin syndrome, but described the occurrence of mania with concomitant use of selegiline and fluoxetine. In the first case (described in 2 separate articles),29,30 the authors thought the prolonged mania resulted from concomitant use of fluoxetine and selegiline, because both medications are known to induce mania when used alone. In the other case, the patient experienced a second manic episode 2 months after discontinuing selegiline. At that point, the authors did not further clarify the patient’s psychiatric diagnosis.34 Mania alone does not fit the Sternbach criteria12 or the HSTC.15

**CLINICAL MANAGEMENT**

The benefits of MAO-B inhibitor and SSRI in combination in the treatment of depression related to Parkinson disease generally outweigh the risks; therefore, either selegiline or
rasagiline can be used cautiously with an SSRI, if their recommended doses are not exceeded (i.e., total daily doses of up to 10 mg and 1 mg for selegiline and rasagiline, respectively) and doses of SSRI are kept at the lower end of the therapeutic range. When adding an SSRI to either selegiline or rasagiline, the SSRI should be initiated at the lowest possible dose and titrated slowly. The use of other serotonergic agents should be avoided; drugs that can decrease the metabolism of either MAO-B inhibitors or SSRIs should also be avoided. Among the SSRIs, cilopram and sertraline may be preferred because of their demonstrated efficacy and tolerability as antidepressants in Parkinson disease.24,5 Sertraline is the SSRI that appears to have the least potential for inducing parkinsonism,4 whereas cilopram has an overall low potential for drug interactions.39 Proper patient monitoring is imperative. According to case reports, the onset of the interaction is variable, ranging from a few days to weeks after initiation of the new agent. Therefore, clinicians must remain vigilant for this interaction at all times. As a cautionary measure, the patient and/or caregiver should be advised of the signs and symptoms of serotonin syndrome, despite the low risk.

**CONCLUSION**

To date, the only report to estimate the incidence of serotonin syndrome with the coadministration of an MAO-B inhibitor and antidepressants (including SSRIs) is the Parkinson Study Group survey.36 In that survey, the authors found an incidence of 0.24%, although these were not cases of serotonin syndrome retroactively assessed using the Sternbach criteria, and the survey report predated the development of the HSTC. Furthermore, the large retrospective study that used a preset definition of serotonin syndrome based on the HSTC did not identify any cases of serotonin syndrome.31 The clinical data supporting this potential interaction are therefore based on case reports alone. Given that the benefits of this combination in treating depression related to Parkinson disease generally outweigh the risks, either selegiline or rasagiline can be used cautiously with an SSRI, provided that their recommended doses are not exceeded and the doses of SSRIs are kept at the lower end of the therapeutic range.

**References**
